Orikine Bio closes €5.5m series seed financing with Sabadell Asabys and AdBio - #BHHMembersInitiatives
Home News Orikine Bio closes €5.5m series seed financing with Sabadell Asabys and AdBio - #BHHMembersInitiatives

Orikine Bio closes €5.5m series seed financing with Sabadell Asabys and AdBio - #BHHMembersInitiatives

JULY 18, 2023 BHH News
Orikine Bio, a biotech company developing a novel proprietary platform for cytokine-based therapies for autoimmune and inflammatory diseases, announces the successful closing of a €5.5m seed financing that will support the company to advance candidates through pre-clinical development. BHH member Asabys Partners, Barcelona-based VC firm focused on healthcare innovation investing from its fund Sabadell Asabys II, joins AdBio Partners, French life sciences venture capital firm and initial investor. Orikine Bio is a spin-off from the Centre for Genomic Regulation (CRG) in Barcelona and was co-founded by Dr. Luis Serrano, Dr. Ariadna Montero, Dr. Javier Delgado, Dr. Alejo Chorny and AdBio Partners in 2022. The company’s unique synthetic biology platform delivers optimized and novel engineered cytokines called Foldikines©. Cytokines are proteins that are produced by the immune system and act as soluble messengers that control the entire range of immune responses, including their initiation, type, potency, and duration. Thus, dysregulated cytokine signaling triggers a wide variety of inflammatory and autoimmune diseases, allergies, fibrosis, and cancer. Orikine Bio's Foldikines© have unique biological activities that are not available for natural cytokines, making them highly attractive as new drugs for therapeutic interventions. Currently, the company is validating the first Foldikine© candidates, which will advance to the pre-clinical stage with this new funding. The initial focus of the company is to advance these improved cytokines into clinical development for new therapies targeting autoimmune and inflammatory diseases. However, the versatility of the platform developed by Dr. Luis Serrano and his team will allow the development of new drugs for a wide range of immune-based diseases. Luis Serrano, co-founder of Orikine Bio and Director of the CRG, mentions: “Orikine Bio is the fifth spin-off launched by the Centre for Genomic Regulation in a short period of time, demonstrating that curiosity-driven research is a critical source for new idea generation and solutions for patients. The creation of this company has been possible thanks to the development of cutting-edge computational and experimental tools combined with decades of expertise in biochemistry”. Dr. Ariadna Montero, co-founder and Head of Biology at Orikine Bio, adds: “Protein design is a highly-precise task requiring accurate algorithms to generate reliable results. Our unique computational approach makes the process of protein design highly flexible and adaptable to almost any target, speeding up the development process for new drugs.” Sylvain Sachot, Partner at Asabys Partners, states “Orikine Bio’s uniqueness resides in the company’s profound understanding of the immunological processes underlying autoimmune and inflammatory diseases and its ability to modulate these anomalies. The company is targeting a large medical need, and we look forward to working with the management in developing and bringing new immune modulators to the market". “Orikine Bio's Foldikines© could become blockbusters drugs in immunology and this immediately convinced us of the potential of the project. We were highly motivated to cofound the company and shape the initial business plan. We are delighted to welcome Asabys Partners in the Seed Financing, all ingredients are in place for Orikine Bio to become a leader in its space” explains Clement Bertholet, MsC, Partner at AdBio. Alejo Chorny, Co-founder and CEO of Orikine Bio, adds “We are delighted to announce the successful completion of our seed financing round, a significant milestone for our biotech company focused on engineered cytokines for immune-mediated diseases. This funding injection not only validates the tremendous potential of our approach but also provides us with the resources to advance our groundbreaking work. We are grateful for the support and confidence shown by our investors and remain committed to delivering transformative therapies that have the power to reshape the lives of patients battling immune-mediated diseases worldwide”.
June 12, 2024 BHH News
Siemens Healthineers and Barcelona Health Hub sign partnership to drive breakthrough innovations for equitable, quality healthcare
This partnership opens a collaboration line between both entities to advance towards a future where medical care and technological advancements help healthcare professionals deliver high-quality care, thus achieving the best possible outcomes for patients.
Read more
June 10, 2024 BHH News
Menarini and Barcelona Health Hub join forces to promote the incorporation of digital health innovation into the healthcare field
Open collaboration and co-creation are the pillars for generating innovation in healthcare. Technological and scientific advances can be significantly accelerated when collaborative environments are fostered.
Read more
June 06, 2024 BHH News
BHH Podcast - Mediktor
BHH member Mediktor joins in this episode with CEO Cristian Pascual.  Listen to Cristian share his journey in revolutionizing healthcare through AI-driven medical triage. 
Read more
June 05, 2024 BHH News
CHV-FHSC signs a strategic alliance with Barcelona Health Hub
This alliance is to carry out joint activities to share concerns and knowledge that lead to the development of new technology projects.
Read more
June 05, 2024 BHH News
BHH ON AIR with Vodafone Business at Revolució 4.0 at Catalunya Ràdio
If you’re looking for a quick catch-up about all things related to digital health, don’t miss BHH this weekend at Catalunya Ràdio!
Read more
May 29, 2024 BHH News
Teladoc Health joins Barcelona Health Hub to support its mission to advance innovation in digital health
Teladoc Health, the world's leading virtual care company, with revenues of 2.6 billion USD in 2023, joins Barcelona Health Hub. 
Read more
May 22, 2024 BHH News
Check out the state of Digital Health in Catalonia
This is your chance to dive deep into the state of digital health in Catalonia with this elaborated by ACCIÓ, in collaboration with Barcelona Health Hub.
Read more
May 09, 2024 BHH News
Explore the 'Sandbox of the System' at the Stage Hospital de la Santa Creu i Sant Pau
Explore the Hospital de la Santa Creu i Sant Pau Stage as the latest track of the Health Revolution Congress on May 16th!
Read more
May 09, 2024 BHH News
BHH ON AIR with Fundació Sant Pau at Revolució 4.0 at Catalunya Ràdio
If you’re looking for a quick catch-up about all things related to digital health, don’t miss BHH this weekend at Catalunya Ràdio!
Read more
May 03, 2024 BHH News
Stage Biocat: New Pathways for the Adoption of Healthcare Innovation in Catalonia
Discover the Biocat morning session as part of the Health Revolution Congress on May 16th.
Read more